Back

Development and optimization of self-collected, field stable, saliva-based immunoassays for scalable epidemiological surveillance of pathogen-specific immunity

Bahr, L. E.; Lu, J. Q.; Buddhari, D.; Hunsawong, T.; Rapheal, E.; Greco, P.; Ware, L.; Klick, M.; Farmer, A.; Middleton, F.; Thomas, S. J.; Anderson, K.; Waickman, A.

2026-03-06 infectious diseases
10.64898/2026.03.05.26347729 medRxiv
Show abstract

Serological surveillance is fundamental to infectious disease research and informed public-health decision making. Immunoassays used in the study of pathogen-specific immunity have historically relied on the collection of venous blood. While critical for many public-health applications, this sample collection method is invasive and resource intensive. The costs and logistical barriers associated with venous blood collection are exacerbated in resource-limited regions, and the shift to less invasive sampling methods would increase sample availability for pathogen surveillance and study of pathogen-specific immunity. To this end, we have developed and optimized a self-collected, saliva-based immunoassay capable of quantifying pathogen-specific antibody binding in saliva samples. Using samples collected from geographically and epidemiologically diverse regions of the world, we compared antigen-specific IgG levels in paired plasma and saliva samples. We observed that levels of IgG against multiple pathogens of public health concern - including SARS-CoV-2 and dengue virus (DENV) - were highly correlated in plasma and swab-collected saliva. In addition, the decay of maternally derived antibodies in saliva samples collected from infants was readily observed using this immunoassay, demonstrating the assays sensitivity and potential for use in measuring antibody kinetics. We posit that this assay represents a climate stable, non-invasive tool that can aid in the surveillance and study of pathogen-specific immunity across a broad range of public-health indications.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3102 papers in training set
Top 6%
10.2%
2
PLOS ONE
4510 papers in training set
Top 21%
8.5%
3
Journal of Clinical Microbiology
120 papers in training set
Top 0.4%
6.4%
4
Viruses
318 papers in training set
Top 0.8%
6.4%
5
The Journal of Immunology
146 papers in training set
Top 0.3%
4.9%
6
Nature Communications
4913 papers in training set
Top 37%
4.0%
7
mSphere
281 papers in training set
Top 2%
3.1%
8
The Journal of Infectious Diseases
182 papers in training set
Top 1%
3.1%
9
Microbiology Spectrum
435 papers in training set
Top 1%
3.1%
10
Emerging Infectious Diseases
103 papers in training set
Top 0.8%
2.8%
50% of probability mass above
11
Analytical Chemistry
205 papers in training set
Top 1.0%
2.8%
12
mBio
750 papers in training set
Top 5%
2.8%
13
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 2%
1.9%
14
Cell Reports Methods
141 papers in training set
Top 2%
1.9%
15
Clinical Chemistry
22 papers in training set
Top 0.3%
1.9%
16
Journal of Immunological Methods
24 papers in training set
Top 0.1%
1.7%
17
Open Forum Infectious Diseases
134 papers in training set
Top 1%
1.7%
18
Clinical Infectious Diseases
231 papers in training set
Top 3%
1.7%
19
Frontiers in Microbiology
375 papers in training set
Top 6%
1.5%
20
PLOS Neglected Tropical Diseases
378 papers in training set
Top 4%
1.3%
21
JCI Insight
241 papers in training set
Top 5%
1.2%
22
Applied and Environmental Microbiology
301 papers in training set
Top 2%
1.0%
23
Journal of Virological Methods
36 papers in training set
Top 0.5%
1.0%
24
mSystems
361 papers in training set
Top 7%
0.8%
25
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 4%
0.8%
26
Pathogens
53 papers in training set
Top 2%
0.7%
27
PLOS Pathogens
721 papers in training set
Top 9%
0.7%
28
Clinical Chemistry and Laboratory Medicine (CCLM)
12 papers in training set
Top 0.3%
0.7%
29
eLife
5422 papers in training set
Top 61%
0.6%
30
PLOS Biology
408 papers in training set
Top 23%
0.6%